Green et al. tested whether Gefinitib as an orally active selective EGFR inhibitor might benefit advanced breast cancer (ABC) patients either with acquired hormone resistance or with hormone receptor (HR)-negative tumors. This evidence concerns the gene NR4A1 and breast carcinoma.